Simtra BioPharma Solutions Expands Manufacturing Capacity with a $250 Million Investment in Bloomington

Simtra BioPharma Solutions' Manufacturing Expansion

On November 9, 2026, Simtra BioPharma Solutions, a leading global contract development and manufacturing organization focused solely on sterile injectables, celebrated the grand opening of its new facility, Building H, at the Bloomington manufacturing campus. The expansion represents a staggering investment of over $250 million, aimed at significantly increasing the company’s capacity to produce sterile injectable products.

During the ribbon-cutting ceremony, dignitaries and local officials gathered to mark this significant addition to the company's operations. Indiana Governor Mike Braun and Bloomington Mayor Kerry Thomson were present, underscoring the economic importance of this project to the local community and the broader pharmaceutical manufacturing sector.

Building H, which spans an impressive 153,000 square feet, introduces advanced capabilities including prefilled syringe production, vial filling, and lyophilization processes. These enhancements are designed to address the diverse and complex needs of customers seeking reliable manufacturing solutions for sterile injectables.

Franco Negron, the CEO of Simtra BioPharma Solutions, emphasized that the opening of this new facility signifies much more than just increased production capacity. It represents a critical step in the company's overarching strategy to expand globally and to better meet the needs of its clients. He remarked, "With substantial investments in both Bloomington and Halle, we are fortifying our global manufacturing network to support the evolving needs of our customers. This will enable us to deliver vital medicines to patients around the world."

In addition to the Bloomington expansion, Simtra is also making significant investments in its Halle, Germany facility, totaling more than $125 million. As part of its strategic growth plan, Simtra aims to increase its filling lines from 11 to 18 by 2027, enhancing its capacity to meet the rising demand for sterile injectables worldwide.

Ray Guidotti, the COO of Simtra BioPharma Solutions, highlighted the importance of forward planning in the manufacturing industry, stating, "Our customers are strategizing for the long term, and they require manufacturing partners who can keep pace with their ambitions. Building H equips us with the necessary capacity in Bloomington to align with our growth strategy and future initiatives."

The opening of Building H is also expected to generate hundreds of high-quality jobs within the Bloomington community, further demonstrating Simtra's commitment to bolstering the local economy. Pat Adams, VP of Expansion Operations, expressed pride in the new facility, noting that it integrates advanced manufacturing technology with robust support systems to ensure a consistent and reliable supply of crucial injectable products.

For over 65 years, Simtra BioPharma Solutions has been at the forefront of the pharmaceutical manufacturing industry, utilizing deep technical expertise to bring complex medicines to market efficiently. With its facilities in both Bloomington, Indiana, and Halle, Germany, Simtra is well-positioned to continue supporting pharmaceutical and biotechnology innovators as they navigate the evolving landscape of drug development.

For more information about Simtra BioPharma Solutions and their commitment to delivering high-quality sterile injectables, visit Simtra's official website.